Mink Therapeutics’ ARDS Trial and Gastric Cancer Data Timelines Clash in Q4 Earnings Call

Date of Call: Mar 31, 2026

Financials Results

• EPS: Net loss for Q4 2025 was $2.6M or $0.56 per share, compared to $2.5M or $0.62 per share for Q4 2024. Full year net loss was $12.5M or $2.93 per share, compared to $10.8M or $2.86 per share in 2024.

Guidance:

• Initiating randomized phase II/III ARDS hypoxemic pneumonia study and GVHD trial in first half of 2026.
• Expect initial clinical data from both programs in second half of 2026.
• Multiple data presentations and peer-reviewed publications planned in first half of 2026.
• Cash balance extended to $16.4M (including $3M raised since year-end) providing runway through 2026.

Business Commentary:

Clinical Progress and Durability:

• MiNK Therapeutics demonstrated durable survival beyond 23 months and complete remission extending beyond 2 years in heavily pretreated refractory cancers.
• This was achieved through the company's allogeneic invariant natural killer T-cell platform, which restores and coordinates immune function across diseases.

Financial Position and Efficiency:

• The company increased its cash position to $13.4 million from $4.6 million, while reducing operating costs by nearly 40% over the year.
• This was made possible through non-dilutive funding and disciplined execution, allowing the company to advance programs without significant dilution.

Pipeline Expansion and Strategic Partnerships:

• MiNK Therapeutics is advancing multiple clinical programs, including a trial for graft versus host disease and a phase II study for severe hypoxemic pneumonia.
• The expansion is supported by non-dilutive funding from NIH, philanthropic support, and consortium funding through C-Further, enabling pipeline growth without incremental capital burden.

Regulatory and Clinical Milestones:

• The company plans to initiate a randomized phase II/III ARDS hypoxemic pneumonia study and expects initial clinical data in the second half of this year.
• This is part of a focused strategy to generate clear, interpretable data for regulatory approval and strategic pathways.

Sentiment Analysis:

Overall Tone: Positive

• CEO highlights 'durable survival beyond 23 months' and 'complete remission extending beyond two years' in cancer. States 'we have increased cash while reducing burn' and 'the story is pretty simple... we demonstrated durability' with 'clear, interpretable data' planned for 2026. Expresses excitement about 'multiple readouts' and 'rapid development pathways'.

Q&A:

• Question from Emily Bodnar (H.C. Wainwright): Could you talk through how many patients approximately that trial is gonna be and what the appropriate control arm is here? Then just talk about development in IPF.
  Response: Trial details not disclosed; control will be physician's choice standard of care. IPF trial design to be announced in coming months, with a special meeting planned.

• Question from Emily Bodnar (H.C. Wainwright): On the second-line gastric cancer trial, could you just remind us the status of that and when we may be able to see efficacy data from that study?
  Response: Efficacy data expected in first half of 2026 at a major conference.

• Question from Mayank Mamtani (B. Riley Securities): On the last point on IPF and even GVHD, what target patient population... and what differentiating aspects... you know, some of the recently approved... approaches... Then on some of the IL-15 iNKT cell combination trial... Could you help us understand how... would inform what you are looking to independently do...
  Response: ARDS trial population defined by hypoxemic pneumonia criteria; control is physician's choice standard of care. Clarified that no formal collaboration with IL-15 superagonist exists; company is actively discussing strategic partnerships but will announce publicly.

Contradiction Point 1

Severe Pulmonary Disease (ARDS) Trial Timeline

Contradiction on the timeline for the first patient dose and initial data for the ARDS trial.

What are the main takeaways from the earnings report? - Emily Bodnar (H.C. Wainwright)

2025Q4: The study will be posted on ClinicalTrials.gov soon, with initial data expected in the second half of 2026. - Dr. Jennifer Buell(CEO)

Can you discuss the phase II pneumonia/ARDS study's size and control arm, as well as your approach to indications like IPF? - Emily Bodnar (H.C. Wainwright & Co, LLC)

2025Q3: The team is in the activation phase, targeting the first patient dose imminently this year or very early in Q1 2026. - Jennifer Buell(CEO)

Contradiction Point 2

Status of the IL-15 iNKT Cell Combination Trial

Contradiction on the status and formalization of collaboration for the IL-15 combination trial.

What was Mayank Mamtani's question to the management during the earnings call? - Mayank Mamtani (B. Riley Securities)

2025Q4: Clarified that the referenced study is the MiNK-sponsored randomized phase II trial not yet posted on ClinicalTrials.gov. The company has not formally announced any collaboration with an IL-15 superagonist. - Dr. Jennifer Buell(CEO)

How will the 30-subject IL-15 iNKT cell trial inform the larger ARDS trial, and do the patient populations overlap? - Emily Bodnar (H.C. Wainwright & Co, LLC)

2025Q3: The combination data with PD-1 in heavily pretreated patients... An externally financed Phase II study is being planned... This will allow for more formal investigation... - Jennifer Buell(CEO)

Contradiction Point 3

ARDS Trial Phase and Regulatory Path

Contradiction on whether the ARDS trial is Phase II or Phase II/III.

Emily Bodnar (H.C. Wainwright) - Emily Bodnar (H.C. Wainwright)

2025Q4: The upcoming randomized phase II study for hypoxemic pneumonia/ARDS... initial data expected in the second half of 2026. - Dr. Jennifer Buell(CEO)

Could you discuss the phase II pneumonia/ARDS study's design, including its size and control arm, and your strategy for expanding into other indications like IPF? - Emily Claudia Bodnar (H.C. Wainwright & Co, LLC)

2025Q2: MiNK is planning announcements soon regarding a **randomized Phase II/III study** for Acute Respiratory Distress Syndrome (ARDS)... - Jennifer S. Buell(CEO)

Contradiction Point 4

Gastric Cancer Trial Data Timeline

Contradiction on the expected timeline for mature gastric cancer data.

Emily Bodnar (H.C. Wainwright): Could you discuss your Q3 performance compared to expectations? - Emily Bodnar (H.C. Wainwright)

2025Q4: Efficacy data from the gastric cancer trial is expected to be presented at a major conference in the **first half of 2026.** - Dr. Jennifer Buell(CEO)

What is the status and timeline for efficacy data from the second-line gastric cancer trial? - Mayank Mamtani (B. Riley Securities)

2025Q2: The Phase II trial... will provide **mature clinical follow-up and survival data by year-end 2025.** - Jennifer S. Buell(CEO)

Contradiction Point 5

Gastric Cancer Trial Efficacy Data Timeline

Contradiction in the expected timing for presenting initial efficacy data.

Emily Bodnar (H.C. Wainwright) - Emily Bodnar (H.C. Wainwright)

2025Q4: Efficacy data from the gastric cancer trial is expected to be presented at a major conference in the first half of 2026. - Jennifer Buell(CEO)

What is the current status and expected timeline for efficacy data from the second-line gastric cancer trial? - Emily Bodnar (H.C. Wainwright)

2025Q1: The company is on track to present initial efficacy data, targeting no later than early next year, but aims for presentation by the end of this year. - Jennifer Buell(CEO)